Melanoma trials in Spain
39 of 50 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 13 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleImmunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer
- Where
- Barcelona, Majadahonda, Valencia
- Age
- 18 years and over
- People
- 180 worldwide
- Run by
- ETOP IBCSG Partners Foundation
See details and how to joinNCT05522660 - Phase 1Taking peopleA Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Where
- Barcelona, Logroño, Madrid
- Age
- 18 years and over
- People
- 124 worldwide
- Run by
- Pliant Therapeutics, Inc.
See details and how to joinNCT06270706 - Phase 1Taking peopleA PK study to compare JPB898 (proposed nivolumab biosimilar) and US-licensed Opdivo® in participants with resected stage IIB, IIC, or III melanoma in the adjuvant setting
- Where
- Badajoz, Barcelona, Cáceres, Granada, Jerez De La Frontera, Las Palmas de Gran Canaria, Lleida, Madrid, Majadahonda, Málaga, Oviedo, Pozuelo de Alarcón, Sabadell, San Cristóbal de La Laguna, Santander, Sevilla, Torrejón de Ardoz, Valencia
- Age
- 18 years and over
- People
- 89 worldwide
- Run by
- H e x a l AG
See details and how to join2025-521919-39-00 - Phase 4Taking peopleDabrafenib and/or Trametinib Rollover Study
- Where
- Barcelona, Madrid, Valencia
- Age
- 18 years to 100 years
- People
- 100 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT03340506 · EU 2023-509318-13-00 - Phase 1Taking peoplePharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma
- Where
- Barcelona, Madrid, Murcia, Sabadell, Sevilla
- Age
- 18 years and over
- People
- 120 worldwide
- Run by
- Biocon Biologics UK PLC
See details and how to joinNCT07476326 · EU 2025-525158-20-00 - Phase 1Taking peoplePhase 1 Study of PF-08046033 in Advanced Solid Tumors
- Where
- Barcelona, Madrid
- Age
- 18 years and over
- People
- 250 worldwide
- Run by
- Pfizer
See details and how to joinNCT07519655 - Phase 2Taking peopleA Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
- Where
- Barcelona, Hospitalet, Madrid, Seville
- Age
- 18 years and over
- People
- 254 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07492680 - Phase 2Taking peopleDB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- Where
- A Coruña, Barcelona, Girona, L'Hospitalet de Llobregat, Logrono
- Age
- 18 years and over
- People
- 750 worldwide
- Run by
- DualityBio Inc.
See details and how to joinNCT06953089 · EU 2025-523895-22-00 - Phase 3Taking peopleStudy to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma
- Where
- Barcelona, Bilbao, Huelva, Lleida, Madrid, Málaga, Sabadell, Seville, Torrejón de Ardoz
- Age
- 18 years and over
- People
- 632 worldwide
- Run by
- mAbxience Research S.L.
See details and how to joinNCT07221734 - Phase 2Taking peopleA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Barcelona, Madrid, Málaga, Seville, Valencia
- Age
- 18 years and over
- People
- 740 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00 - Phase 1/2Taking peopleA Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid, Sevilla
- Age
- 18 years and over
- People
- 680 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00 - Phase 1/2Taking peopleA Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- Where
- Barcelona, Logroño, Madrid, Pozuelo de Alarcón, Valencia
- Age
- 18 years and over
- People
- 1,438 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT07070232 · EU 2024-517261-16-00 - Phase 2/3Taking peopleSafety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
- Where
- Badalona, Barcelona, Cáceres, Girona, Jerez de la Frontera, Las Palmas de Gran Canaria, Lugo, Madrid, Málaga, Murcia, Santander, Santiago de Compostela, Valencia
- Age
- 18 years and over
- People
- 740 worldwide
- Run by
- Eikon Therapeutics
See details and how to joinNCT06697301 · EU 2024-512659-19-00 - Phase 2Not yet taking people in SpainPHOENIX - ECP: Extracorporeal PHotopheresis for immune-related cOlitis and/or hEpatitis in advanced melaNoma with inadequate response to steroId eXposure
- Where
- Barcelona, Madrid, Murcia
- Age
- 18 years and over
- People
- 46 worldwide
- Run by
- Therakos Europe Limited
See details and how to join2026-526261-14-00 - Phase 3Taking peopleStudy to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Pamplona, Pozuelo de Alarcón, Santander, Sevilla, Valencia
- Age
- 18 years to 70 years
- People
- 670 worldwide
- Run by
- Iovance Biotherapeutics, Inc.
See details and how to joinNCT05727904 · EU 2022-503140-41-00 - Phase 1/2Taking peopleBI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
- Where
- Barcelona, Madrid
- Age
- 18 years and over
- People
- 250 worldwide
- Run by
- BioInvent International AB
See details and how to joinNCT04752826 · EU 2023-509847-29-00 - Phase 2Taking peopleNeoadjuvant Tebentafusp in Patients With Metastatic Uveal Melanoma
- Where
- L'Hospitalet de Llobregat, Madrid, Valencia
- Age
- 18 years and over
- People
- 19 worldwide
- Run by
- Grupo Español Multidisciplinar de Melanoma
See details and how to joinNCT07057596 · EU 2023-509076-42-00 - Phase 1Taking peopleA Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
- Where
- Barcelona, Las Palmas de Gran Canaria, Madrid, Málaga, Seville, Valencia
- Age
- 18 years and over
- People
- 400 worldwide
- Run by
- Pierre Fabre Medicament
See details and how to joinNCT04913285 - Phase 1Taking peoplePharmacokinetic Similarity Study to Compare AVT32-DRL_PB With Keytruda® in Participants With Fully Resected Melanoma
- Where
- Badalona, Barcelona, Cáceres, L'Hospitalet de Llobregat, Madrid, Málaga, Pozuelo de Alarcón, Sevilla
- Age
- 18 years and over
- People
- 120 worldwide
- Run by
- Alvotech Swiss AG
See details and how to joinNCT07475572 · EU 2025-525093-11-00 - Phase 1/2Taking peopleA Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- Where
- Badalona, Barcelona, Madrid, Málaga, Pamplona
- Age
- 18 years and over
- People
- 1,109 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT04895709 - Phase 1/2Taking peopleA Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Where
- Barcelona, Madrid, Valencia
- Age
- 18 years and over
- People
- 366 worldwide
- Run by
- Marengo Therapeutics, Inc.
See details and how to joinNCT05592626 · EU 2023-505334-10-01 - Phase 1Taking peopleSafety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours
- Where
- Barcelona, Madrid, Valencia
- Age
- 18 years and over
- People
- 106 worldwide
- Run by
- MonTa Biosciences ApS
See details and how to joinNCT04855435 · EU 2024-512294-26-00 - Phase 2Taking peoplePhase II randomized study evaluating a Pragmatic approach to Adoptive Cell Therapy (ACT) using an IL2 analog (ANV419/ANV600) vs High dose IL2 after Tumor Infiltrating Lymphocytes (TIL) Therapy in patients with melanoma, NSCLC and cervical cancer. The PragmaTIL
- Where
- Barcelona
- Age
- 18 years and over
- People
- 24 worldwide
- Run by
- Vall D Hebron Institute Of Oncology
See details and how to join2023-506400-99-00 - Phase 2Taking peoplePhase II study of Roginolisib in UM patients
- Where
- L'Hospitalet de Llobregat, Madrid, Santiago de Compostela, Sevilla, Valencia
- Age
- 18 years and over
- People
- 43 worldwide
- Run by
- iOnctura SA
See details and how to join2024-514333-37-00 - Phase 3Taking peopleVO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
- Where
- Barcelona, Madrid, Murcia, Pamplona
- Age
- 12 years and over
- People
- 400 worldwide
- Run by
- Replimune, Inc.
See details and how to joinNCT06264180 · EU 2023-508612-29-00